Genetic Profiling May Guide Hormone Therapy for Prostate Cancer Post-Surgery

This analysis of the NRG-RTOG 0534 'SPPORT' clinical trial used the PAM50 genomic classifier to evaluate the Luminal B molecular subtype in prostate cancer. The study aims to determine if tumor biology can identify patients who would benefit most from hormone therapy after surgery. This approach could personalize treatment plans based on genetic profiling.

Originally published by gnews